Browse by Industry
Filter News
Found 55,743 articles
-
Researchers at the University of California at San Francisco have discovered that a scorpion toxin can actually be harnessed to target the wasabi receptor, which is described as a “chemical-sensing protein” found in nerve cells.
-
In Wake of Terminations, Pharma Leaders Decry Actions That Will Limit Collaborations with Foreign...
8/23/2019
Leaders from across the pharmaceutical industry are decrying negative actions taken by government agencies and universities against Chinese researchers in the United States. -
The new company, which was founded earlier this year, will take a similar approach to treat kidney disease that oncologists have taken with cancer.
-
BioSpace Movers & Shakers, Aug. 23
8/23/2019
Biopharma companies strengthen their senior leadership teams and boards of directors with this week's appointments. -
In a head-to-head study, BeyondSpring’s plinabulin stood up to Amgen’s Neulasta (pegfilgrastim) in a quality of life study to prevent neutropenia, a common side effect for chemotherapy patients.
-
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
-
Eli Lilly won an arbitration hearing over accusations the Indianapolis-based company misused confidential information regarding the intellectual property of its former business partner, France-based Adocia S.A.
-
Phoenix Continuum Recovery Center Receives Nationwide Buzz About Drug Detox Medical Device
8/23/2019
When Continuum Recovery Center (CRC) announced earlier this year that it was offering the first non-pharmaceutical, non-implantable, FDA-cleared medical device to clients struggling with opioid dependency, its staff knew this was a game-changer for drug treatment.
-
Antimicrobial Susceptibility Testing Market Outlook 2019 – 2023: Government Initiatives to Boost Growth | Technavio
8/23/2019
The global antimicrobial susceptibility testing market size is poised to reach USD 832.14 million by 2023, according to a new report by Technavio, progressing at a CAGR of 5% during the forecast period.
-
Tmunity Announces Participation at Upcoming Investor Conferences
8/23/2019
Tmunity Therapeutics, Inc. announced that Usman “Oz” Azam, MD, President and Chief Executive Officer, and members of the management team plan to participate at two investor conferences in September and October 2019.
-
Disarm Therapeutics Announces Science Publications Elucidating Structure and Function of SARM1
8/23/2019
Disarm Therapeutics, a biotechnology company creating a new class of disease-modifying therapeutics for patients with axonal degeneration, today announced the publication of two articles in Science that significantly advance the understanding of the structure and function of SARM1, a protein that is a critical regulator of cellular degeneration, and provide further support for the centrality of the NAD+-cleavage pathway in mediating cellular degeneration across multiple species.
-
Nevro to Present at Morgan Stanley 17th Annual Healthcare Conference
8/23/2019
Nevro Corp. announced the Company will be participating in the Morgan Stanley 17th Annual Healthcare Conference in New York City.
-
How Demand Management Helped a Medical Device Company Achieve Savings of Over $5.2 Million | Infiniti Research’s Latest Success Story
8/23/2019
Infiniti Research, a leading market intelligence solutions provider, has recently announced the completion of their latest demand management solution for a medical device company.
-
HotSpot Therapeutics Announces Acquisition of Macroceutics, Inc.
8/23/2019
--- HotSpot to gain access to Macroceutics' custom DNA-encoded libraries comprising approximately one billion compounds with full screening and chemistry capabilities --- Libraries to be integrated into HotSpot's SpotFinder™ platform which predicts, drugs and differentiates allosteric regulatory sites [23-August-2019] BOSTON , Aug. 23, 2019 /PRNewswire/ -- H
-
Study Uncovers a Strategy that Viruses use to Evade Immediate Immune Responses
8/23/2019
Researchers at the U.S. Naval Research Laboratory have identified a new algorithm that could help virologists better understand and treat infections caused by viruses like the Zika virus.
-
West Announces Participation in Upcoming September Investor Conferences
8/23/2019
West Pharmaceutical Services, Inc. announced that management will present an overview of the business at two investor conferences in September.
-
OxThera Receives Positive Decision From EMA on Paediatric Investigational Plan (PIP) for Treatment of Primary Hyperoxaluria With Oxalobacter formigenes
8/23/2019
OxThera AB announced that, based on a positive opinion from the Paediatric Committee, the EMA has agreed to the proposed PIP for Oxalobacter formigenes in the treatment of primary hyperoxaluria.
-
Cantargia and BioWa Extend Ongoing Collaboration around the POTELLIGENT® Technology
8/23/2019
Cantargia AB and BioWa Inc. have signed an extension of the license agreement around the BioWa proprietary POTELLIGENT® Technology for production of Cantargia’s antibody drug candidate CAN04, which gives Cantargia broader rights to use the technology.
-
CStone announces data from trials of CS1001, CS1002 and CS1003 to be released for the first time at 2019 CSCO Annual Meeting
8/23/2019
CStone Pharmaceuticals announced that the 22nd Annual Meeting of the Chinese Society of Clinical Oncology has accepted three abstracts on the clinical trials of CS1001, CS1002, and CS1003, the Company's three backbone immunotherapy candidates.
-
CStone completes registration filing for the Phase I trial of CDK4/6 inhibitor CS3002 in Australia and will soon initiate the study
8/23/2019
CStone Pharmaceuticals announced that the Company has recently received ethics approval from the Human Research Ethics Committee in Australia for the Phase I clinical trial of CS3002, and Australia's Therapeutic Goods Administration has acknowledged the electronic Clinical Trial Notification the Company submitted for the trial.